Sens. Max Baucus (D-MT) and Chuck Grassley (R-IA) say the FDA continues to suppress scientific dissent and punish agency staff who raise safety issues. In a letter to the FDA commissioner, the senators say an unnamed senior FDA official has been sidelined after voicing concerns about the safety of GlaxoSmithKline’s diabetes drug Avandia.
From the September 01, 2007 Issue of MM+M - Medical Marketing and Media
